CogState sales topped $1m in 2004-05

Melbourne-based neurodiagnostic specialist CogState (ASX:CGS) says its sales exceeded AUD$1 million in sales for the 2004-05 fiscal year, up 420 per cent on the previous year, largely through sales to major pharmaceutical companies and research institutions.

In the past year, CogState has received more than $500,000 from contracts with Pfizer, Organon and Roche for the use of its technology in six Phase I and two Phase III trials. The majority of CogState's sales (80 per cent) have come from the provision of cognitive testing to clinical trials.

In addition, the company has provided the CogState technology to the Centers for Disease Control and Prevention for a US wide trial of cognition in people with HIV.

CogState's other main source of revenue comes from concussion testing by sporting associations such as the AFL, NFL, Australian Rugby Union and the UK Rugby Football League.